NCT03506542 is a Phase 2 clinical trial of Ologen in Glaucoma, sponsored by Medical University of Lublin.

Who is sponsoring NCT03506542?

NCT03506542 is sponsored by Medical University of Lublin.

What drugs are being tested in NCT03506542?

Interventions in NCT03506542: Ologen, Phacotrabeculectomy, Mitomycin C.

What condition does NCT03506542 study?

NCT03506542 studies Glaucoma, Cataract, Wound Heal.

Is NCT03506542 still recruiting?

NCT03506542 is currently completed. Last updated 25 April 2018.

Last reviewed 2018-04-25 · How we verify

NCT03506542

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Phacotrabeculectomy With Collagen Matrix Implant (Ologen®) Versus Mitomycin C

Completed Phase 2 Last updated 25 April 2018

What this trial tests

Phase 2 trial testing Ologen in Glaucoma in 53 participants. Completed in 30 March 2017.

Timeline

2 June 2014

Primary endpoint
1 March 2016

30 March 2017

Quick facts

Lead sponsor	Medical University of Lublin
Phase	Phase 2
Status	Completed
Study type	INTERVENTIONAL
Allocation	randomized
Design	parallel
Masking	none
Primary purpose	treatment
Enrollment	53
Start date	2 June 2014
Primary completion	1 March 2016
Estimated completion	30 March 2017

Drugs / interventions tested

Ologen
Phacotrabeculectomy
Mitomycin C — full drug profile →

Conditions studied

Glaucoma — all drugs for Glaucoma →
Cataract — all drugs for Cataract →
Wound Heal — all drugs for Wound Heal →

Sponsor

Medical University of Lublin

Who can join

18 and older, any sex, with Glaucoma or Cataract. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

1. Study objective: To assess the efficacy and safety of collagen matrix implant (Ologen®; OLO) in phacotrabeculectomy and to compare with mitomycin C (MMC) augmented phacotrabeculectomy. 2. Study Design: The study is designed as a prospective randomized trial. Patient who meet the inclusion/exclusion criteria and sign the informed consent form will be included for this study. 3. Follow-Up: This investigation is including 7 post-operative visits and follow-up within 12 months from the date of surgery. Patients should be seen at postoperative days 1, 7, 30, 90, 180, 270 and 360.

Publications & conference data

No peer-reviewed publications indexed yet for this trial. Completed trials usually publish results within 12-18 months.

Verify or expand the search:

Other trials of Ologen

Trials testing the same drug.

NCT02990143 — The Effectiveness of Ologen® Collagen Matrix in Preventing Intraocular Pressure (IOP) Spikes After Ahmed Glaucoma Valve · Phase 2 · terminated

Other recruiting trials for Glaucoma

Currently open trials in the same condition.

NCT07455786 — Modified Trabeculectomy After Failure of Combined Phaco With GATT · NA · recruiting
NCT07298356 — Automated Applanation Tonometry - Updated · NA · recruiting
NCT07217678 — Biomarkers of Ocular Surface Damage in the Setting of Topical Ocular Hypotensive Medication Use · Phase 4 · recruiting
NCT07145073 — Repetitive Transcranial Alternating Current Stimulation (rtACS) for the Treatment of Optic Neuropathies · NA · recruiting
NCT07209410 — Evaluating Injection With the Use of Brimonidine Tartrate Ophthalmic 0.025% on Patients Using Netarsudil 0.02%/Latanopro · Phase 4 · recruiting

Other Medical University of Lublin trials

Trials by the same sponsor.

NCT07085286 — Perfusion Related Evaluation of Systemic and Renal Vulnerability to Events in CABG · not yet recruiting
NCT06897436 — Characterization of Immune Cells and Their Secreted Cytokines in Endometriosis Patients · not yet recruiting
NCT06516835 — Diluted and Undiluted Enteral Nutrition · NA · not yet recruiting
NCT07182318 — Validation of the FIGO Nutrition Checklist in Pregnant Women · completed
NCT06282666 — Lumbar ESPB in Hip Replacement Surgery · NA · recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03506542 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Medical University of Lublin
Last refreshed: 25 April 2018

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03506542.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing